 | |
| Company type | Subsidiary |
|---|---|
| NYSE: CTLT (2014–2024) | |
| Industry | Pharmaceuticals |
| Predecessor | Cardinal Health PTS |
| Founded | 2007; 19 years ago (2007) |
| Headquarters | Tampa, Florida, U.S. |
Number of locations | 53 (2024) |
Key people |
|
| Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
| Revenue |  US$4.38 billion (2024) |
 US$−749 million (2024) | |
| US$−1.04 billion (2024) | |
| Total assets | US$9.75 billion (2024) |
| Total equity | US$3.60 billion (2024) |
Number of employees | 16,900 (2024) |
| Parent | Novo Holdings A/S |
| Website | catalent |
| Footnotes / references Financials as of June 30, 2024[update].[1] | |
Catalent, Inc. (Catalent Pharma Solutions), headquartered inTampa, Florida and a subsidiary ofNovo Holdings A/S, is a provider of drug delivery technologies,drug development,drug manufacturing,biologics,gene therapy, and consumer health products. It has over 50 facilities on four continents and has supported more than half the products approved by theFood and Drug Administration in the last ten years. Annually, it produces 70 billion doses for 8,000 products. The company's major customers includeBayer,Bristol-Myers Squibb,GlaxoSmithKline,Haleon,Novo Nordisk,Moderna,Pfizer, andSarepta Therapeutics.[1]
In 1996,Cardinal Health acquired PCI ofPhiladelphia, Pennsylvania, a pharmaceutical contract packing service for commercial and clinical packaging.[2][3]
In 1998, Cardinal Health acquired R.P. Scherer Corporation ofTroy, Michigan for $2.2 billion; it was founded byRobert Pauli Scherer to commercialize his innovation ofsoftgel encapsulation using the rotary die production process.[4][5][6]
In 1999, Cardinal Health acquired Automatic Liquid Packaging ofWoodstock, Illinois, thereby entering the sterile product market withblow fill seal technology.[7]
In January 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oralmodified-release dosage form development and manufacturing, for $40 million.[8] In April 2002, Cardinal Health acquired Magellan Laboratories, a company that specialized in product development expertise.[9]
In October 2003, Cardinal Health acquired Gala Biotech ofMadison, Wisconsin for $15.5 million.[10]
It also acquired Intercare Group of the UK for $530 million, broadening its global capabilities in Europe.[11]
In April 2007, the pharmaceutical technologies and services segment of Cardinal Health was acquired by affiliates ofThe Blackstone Group and re-branded asCatalent Pharma Solutions.[12][13]
In February 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[14][15] Catalent also acquired all remaining shares for the R.P Scherer site inEberbach, Germany.[6][16]
In March 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology, a China-based company, and Relthy Laboratories in Brazil.[17][18]
In July 2014, Catalent became apublic company via aninitial public offering on the New York Stock Exchange, raising $870 million.[19][20]
In November 2014, Catalent acquired Micron Technologies, a provider of particle size engineering technologies, expanding its portfolio of drug delivery technologies.[21]
In September 2016, Catalent acquired Pharmatek Laboratories to add spray drying capabilities.[22][23]
In October 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help withoncology development,[24]
In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, expanding its biologic manufacturing.[25]
In July 2018, Catalent acquired Juniper Pharmaceuticals for $133 million.[26]
In March 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes newZydis lines; changes to facilities inSwindon, UK; and a custom suite for commercial equipment.[27]
In September 2018, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine forParkinson's disease utilizing the Zydis delivery method.[28]
In May 2019, Catalent acquired Paragon Bioservices for $1.2 billion to expand its gene-therapy manufacturing capabilities.[29][30] By October 2019, Paragon's employee count doubled since the April acquisition.[31]
In January 2020, Catalent purchased a manufacturing facility located inAnagni, Italy, fromBristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[32]
In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million, to expand into cell therapy development.[33][34]
In 2020, Catalent partnered with multiple drugmakers, includingPfizer,Johnson & Johnson,[35]AstraZeneca,[36] andModerna[37] to provide manufacturing, vial filling and packaging capabilities forCOVID-19 vaccines.[38][39] In the partnership with AstraZeneca, Catalent provided manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[40] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's facility inSt. Petersburg, Florida.[41]
In August 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[42] That month, Catalent also acquired Bettera Holdings, a nutritional supplement company, for $1 billion to provide capability to manufacture vitamins, minerals and supplements in gummy form.[43]
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility inShiga, Japan.[44]
In August 2022, the company acquired Metrics Contract Services, acontract manufacturing organization, for $475 million.[45]
In October 2022, Catalent announced a $12M expansion at aKansas City, Missouri facility.[46]
In January 2023, Catalent partnered withSarepta Therapeutics to manufacturedelandistrogene moxeparvovec (SRP-9001). Sarepta's most advancedgene therapy candidate for the treatment ofDuchenne muscular dystrophy (DMD).[47][48]
In December 2024,Novo Holdings A/S acquired Catalent for $16.5 billion. As part of the transaction,Novo Nordisk acquired three manufacturing facilities from parent Novo Holdings for $11 billion to scale up production to meet the demand ofWegovy andOzempic.[49][50]
| # | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue ($ billions) | 1.85 | 2.08 | 2.46 | 2.52 | 3.09 | 3.998 | 4.828 | 4.863 |
| Total Current Assets ($ billions) | 3.09 | 2.45 | 4.53 | 6.18 | 7.78 | 9.112 | 10.507 | 10.777 |
| Net Operating Cash Flow ($ millions) | 155.3 | 299.5 | 374.5 | 247.7 | 440.3 | 585 | 519 | −256 |
